Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775183 | 0.88 | KMT2A (0.44) | KMT2AMEN1OPRM1OPRD1P2RX7 | |
| SCHEMBL15418113 | 0.83 | MTNR1A (0.39) | KMT2AMEN1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL10381880 | 0.81 | MEN1 (0.52) | KMT2AMEN1OPRM1OPRD1P2RX7 | |
| SCHEMBL2373934 | 0.80 | P2RX7 (0.43) | KMT2AP2RX7 | |
| SCHEMBL1135252 | 0.80 | ALDH1A1 (0.48) | KMT2AMEN1OPRM1OPRD1RAB9A | |
| SCHEMBL6900384 | 0.79 | P2RX7 (0.46) | KMT2AMEN1OPRM1OPRD1P2RX7 | |
| SCHEMBL22633342 | 0.79 | MRGPRX4 (0.45) | RAB9ANPSR1GRM5NPC1SMN1; SMN2 | |
| SCHEMBL15728140 | 0.78 | KMT2A (0.34) | KMT2ARAB9ANPSR1ALDH1A1KDM4E | |
| SCHEMBL30191609 | 0.78 | KMT2A (0.41) | KMT2AMEN1OPRM1OPRD1P2RX7 | |
| SCHEMBL22035812 | 0.78 | KMT2A (0.41) | KMT2AMEN1OPRM1OPRD1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954686-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | Calithera Biosciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-2920168-B1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | CALITHERA BIOSCIENCES, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| CN-102917588-B | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-08 | — | — | CN | disclosed |
| US-20140194421-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194421-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7732457-B2 | Amino-pyridines as inhibitors of β-secretase | WYETH LLC (US) | 2010-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | GLS, GLS2, GLUL | KMT2A 910/4885MEN1 923/4885OPRM1 4852/4885 |
| US-20140194421-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | KMT2A 910/4885MEN1 923/4885OPRM1 4852/4885 |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | KMT2A 910/4885MEN1 923/4885OPRM1 4852/4885 |
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | BACE1, BACE2, APP | KMT2A 1977/4885MEN1 3588/4885OPRM1 4535/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | KMT2A 533/4885MEN1 1270/4885OPRM1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.